(E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate

Base Information

• Chemical Name: (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate
• CAS No.: 61718-82-9
• Molecular Formula: C15H21F3N2O2^.C4H4O4
• Molecular Weight: 434.413
• Hs Code.: 29280000
• European Community (EC) Number: 612-212-6
• Wikidata: Q27262521
• NCI Thesaurus Code: C29063
• RXCUI: 203143
• Mol file: 61718-82-9.mol

Synonyms:Desiflu;DU 23000;DU-23000;DU23000;Dumirox;Faverin;Fevarin;Floxyfral;Fluvoxadura;Fluvoxamin AL;Fluvoxamin beta;Fluvoxamin neuraxpharm;Fluvoxamin ratiopharm;Fluvoxamin Stada;Fluvoxamin-neuraxpharm;Fluvoxamin-ratiopharm;Fluvoxamina Geminis;Fluvoxamine;Fluvoxamine Maleate;Fluvoxamine Maleate, (E)-Isomer;Fluvoxamine, (Z)-Isomer;Geminis, Fluvoxamina;Luvox;Novo Fluvoxamine;Novo-Fluvoxamine;Nu Fluvoxamine;Nu-Fluvoxamine;PMS Fluvoxamine;PMS-Fluvoxamine;ratio Fluvoxamine;ratio-Fluvoxamine

Chemical Property of (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate

Chemical Property:

• Appearance/Colour: white crystalline powder
• Melting Point: 120-121.5 °C
• Boiling Point: 370.6 °C at 760 mmHg
• Flash Point: 177.9 °C
• PSA: 131.44000
• LogP: 3.61360
• Storage Temp.: 2-8°C
• Solubility.: H2O: soluble
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 11
• Rotatable Bond Count: 11
• Exact Mass: 434.16647101
• Heavy Atom Count: 30
• Complexity: 446

Purity/Quality:

99%, ^*data from raw suppliers

Fluvoxamine maleate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn; Xi
• Hazard Codes: Xn,Xi
• Statements: 22-36/37/38
• Safety Statements: 36-36/37/39-27-26

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F.C(=CC(=O)O)C(=O)O
• Isomeric SMILES: COCCCC/C(=N/OCCN)/C1=CC=C(C=C1)C(F)(F)F.C(=C\C(=O)O)\C(=O)O
• Recent ClinicalTrials: Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community
• Recent EU Clinical Trials: A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-19 patients
• Description: Fluvoxamine maleate is the most recent of the serotonin-specific antidepressants to reach the market. In vitro and in vivo animal experiments have shown fluvoxamine to have a marked effect on 5-HT mediated processes and little effect on norepinephrine. Clinical trials suggest similar efficacy to imipramine and clomipramine with a somewhat lower incidence of side effects, especially anticholinergic effects. Fluvoxamine, in contrast to the tricyclic antidepressants, does not appear to produce heart rate increase, postural hypotension or prolongation of the intraventricular conduction time and QT interval.
• Uses: A selective serotonin reuptake inhibitor (SSRI) used as an anti-depressant. Antiobsessional. nonsteroidal anti-inflammatory reduces pain and inflammation in eyes Anxiety disorder Fluvoxamine maleate has been used as a test compound to determine the solubility and effective blood-brain barrier permeability.(2)
• Therapeutic Function: Antidepressant
• Clinical Use: SSRI antidepressant:DepressionObsessive compulsive disorder
• Drug interactions: Potentially hazardous interactions with other drugsAminophylline and theophylline: increased aminophylline and theophylline concentrations - avoid; if not possible, halve aminophylline or theophylline dose and monitor levels.Analgesics: increased risk of bleeding with aspirin and NSAIDs; risk of CNS toxicity increased with tramadol; concentration of methadone possibly increased.Anti-arrhythmics: increased risk of toxicity with mexiletine.Anticoagulants: effect of coumarins possibly enhanced; possibly increased risk of bleeding with dabigatran.Antidepressants: avoid with reboxetine, MAOIs, moclobemide and St John’s wort; possibly enhanced serotonergic effects with mirtazapine; fluvoxamine inhibits metabolism of duloxetine - avoid; can increase tricyclics concentration; metabolism of agomelatine reduced; possible increased risk of convulsions with vortioxetine.Antiepileptics: antagonise anticonvulsant threshold; concentration of carbamazepine, fosphenytoin and phenytoin increased.Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol.Antipsychotics: concentration of asenapine, haloperidol, clozapine and olanzapine increased; increased risk of ventricular arrhythmias with droperidol and possibly pimozide - avoid.Antivirals: concentration possibly increased by ritonavir.Ciclosporin: may increase ciclosporin concentration.Clopidogrel: possibly reduced antiplatelet effect.Cytotoxics: concentration of pomalidomide increasedDapoxetine: possible increased risk of serotonergic effects - avoid.Dopaminergics: increased risk of CNS toxicity with rasagiline - avoid; hypertension and CNS excitation with selegiline - avoid. 5HT1 agonists: risk of CNS toxicity increased with sumatriptan; possibly increased risk of serotonergic effects with naratriptan; inhibits metabolism of frovatriptan; possibly inhibits metabolism of zolmitriptan - reduce zolmitriptan dose.Linezolid: use with care, possibly increased risk of side effects.Lithium: increased risk of CNS effects - monitor levels.Melatonin: concentration of melatonin increased - avoid.Methylthioninium: risk of CNS toxicity - avoid if possible.Muscle relaxants: increased risk of toxicity with tizanidine - avoidPirfenidone: concentration of pirfenidone increased - avoid.

Technology Process of (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate

There total 2 articles about (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one (61718-80-7) + 2-chloroethanamine hydrochloride (870-24-6) + maleic acid (110-16-7,26099-09-2) → fluvoxamine maleate (61718-82-9,917096-37-8)

Guidance literature:

5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one; 2-chloroethanamine hydrochloride; With potassium hydroxide; In water; dimethyl sulfoxide; toluene; at 40 - 45 ℃;

maleic acid; In water; at 20 - 30 ℃;

Reference yield:

1-N-hydroxy-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-imine (61747-22-6) + 2-chloroethanamine hydrochloride (870-24-6) + maleic acid (110-16-7,26099-09-2) → fluvoxamine maleate (61718-82-9,917096-37-8)

Guidance literature:

With potassium hydroxide; In water; toluene;

Reference yield: 8.0%

C14H17N3O2 + fluvoxamine maleate (61718-82-9,917096-37-8) → S-rivastigmine-fluvoxamine

Guidance literature:

With sodium hydrogencarbonate; In dichloromethane; Product distribution / selectivity;

upstream raw materials:

1-N-hydroxy-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-imine

2-chloroethanamine hydrochloride

maleic acid

5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one

Downstream raw materials:

Demethyl Fluvoxamine

Refernces

• 1、 -. "Process for the preparation of fluvoxazmine maleate". . . Retrieved 2008/06/13.